Mitolactol [antikvár]

INTRODUCTION The synthesis of the terminally bifunctional hexitol derivatives and the recognition of their cytostatic activity is among the most important achievements of Hungarian chemotherapeutic research in the last decades. One of the representatives of this group of cytostatic compounds exhibiting the broadest antitumour spectrum is MITOLAC-TOL (dibromodulcitol, ELOBROMOL®), an orally applicable cytostatic drug. Dibromodulcitol was developed by INSTITÓRIS, L. and HORVÁTH, LP. from 1965 to 1968 [106, 129]. Its antineoplastic activity and pharmacologic properties were described by KELL-NER, B. and NÉMETH, L. in 1967 [162]. The pharmacokinetic and metaboHc studies of DBD were started by INSTITÓRIS, L. and HORVÁTH, I. P. in 1967 [134,135]. The first cHnical trials were performed by ECKHARDT, S. and SELLEI, C. in 1969 [248] in the therapy of leukaemias, haemoblastoses and solid tumours. Biochemical, ultrastructural and pharmacobiochemical investigations into the mechanism of action of DBD were initiated by HÍDVÉGI, E. J. [91], LAPIS, K. [179], and JENEY, A. [145]. The details of the mechanism of the interaction between DBD and the tumour cell DNA were investigated by INSTITÓRIS, E. [125]. The antineoplastic effect of DBD has since been extensively studied at laboratories and cHnics of numerous countries.